ValuEngine cut shares of Zynex Inc. (OTCMKTS:ZYXI) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
Zynex (OTCMKTS:ZYXI) last posted its quarterly earnings data on Monday, August 14th. The company reported $0.05 earnings per share (EPS) for the quarter. Zynex had a net margin of 18.12% and a negative return on equity of 86.24%. The company had revenue of $5.04 million during the quarter.
Zynex Company Profile
Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Zynex Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zynex Inc. and related companies.